New Stock News | Noring Biotech Re-submits Application to the Hong Kong Stock Exchange

According to the Hong Kong Stock Exchange's disclosure on August 28, Nanjing Nuoling Biotechnology Co., Ltd. (referred to as: Nuoling Bio) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CMB International as its sole sponsor. The prospectus shows that Nuoling Bio was established in 2018 and operates in the gas pulmonary equipment market, focusing on the research and commercial application of inhaled nitric oxide (iNO) therapy. As of the latest feasible date, the company has five approved products (including a core product, iNOwill) and five candidates under research, covering areas of critical care, ward, outpatient, and home disease management in cardiopulmonary diagnosis and treatment, including three major product lines: (i) iNO therapy; (ii) cardiopulmonary circulation support; and (iii) exhalation diagnosis.